BTIG Research Raises Masimo (NASDAQ:MASI) Price Target to $166.00

Masimo (NASDAQ:MASI) had its price objective hoisted by BTIG Research from $145.00 to $166.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

Other analysts have also issued research reports about the stock. Piper Sandler increased their price objective on shares of Masimo from $70.00 to $117.00 and gave the stock a neutral rating in a research note on Monday, February 26th. Needham & Company LLC lowered shares of Masimo from a buy rating to a hold rating in a research report on Wednesday, January 3rd. Wells Fargo & Company raised shares of Masimo from an equal weight rating to an overweight rating and raised their price target for the stock from $117.00 to $160.00 in a research note on Monday. StockNews.com downgraded shares of Masimo from a hold rating to a sell rating in a research note on Thursday, March 21st. Finally, Jefferies Financial Group reissued a hold rating and issued a $121.00 price target (up from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Masimo presently has a consensus rating of Hold and an average target price of $134.29.

Masimo Trading Up 2.7 %

NASDAQ:MASI opened at $144.48 on Monday. Masimo has a one year low of $75.22 and a one year high of $198.00. The firm has a 50-day simple moving average of $131.76 and a 200-day simple moving average of $109.26. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18. The firm has a market cap of $7.64 billion, a P/E ratio of 95.68 and a beta of 0.95.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.43. The business had revenue of $548.90 million during the quarter, compared to analysts’ expectations of $545.69 million. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the company posted $1.32 earnings per share. Equities analysts anticipate that Masimo will post 3.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MASI. BlackRock Inc. lifted its position in shares of Masimo by 3.0% during the 2nd quarter. BlackRock Inc. now owns 6,120,123 shares of the medical equipment provider’s stock worth $1,007,066,000 after buying an additional 178,267 shares during the last quarter. Vanguard Group Inc. raised its position in Masimo by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider’s stock worth $560,421,000 after buying an additional 26,473 shares during the last quarter. Capital Research Global Investors raised its position in Masimo by 6.4% during the 4th quarter. Capital Research Global Investors now owns 2,269,189 shares of the medical equipment provider’s stock worth $265,972,000 after buying an additional 136,617 shares during the last quarter. State Street Corp raised its position in Masimo by 1.6% during the 1st quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider’s stock worth $251,928,000 after buying an additional 27,261 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Masimo by 6.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,607,310 shares of the medical equipment provider’s stock worth $188,393,000 after purchasing an additional 93,861 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.